Chordate Medical’s joint venture submits application for product registration in China

Chordate Medical and Nanos Medical's joint venture Changyong Medical Technology Co. has submitted an application for product registration for the K.O.S treatment for chronic rhinitis in China.

“This is an important step towards market access in China. The next step in the project is entirely dependent on the answers we get from the Chinese supervisory authority's review work”, says Anders Weilandt, CEO of Chordate.

Chordate and Nanos Medical started a joint venture in 2018, forming the jointly owned company Changyong Medical Technology Co in Shanghai with the intention of marketing the K.O.S technology in the Chinese market. Nanos Medical owns two-thirds of this company and is the party that finances marketing and sales. Chordate owns the remaining third and will supply the Chinese patents when market authorization and product registration are in place.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact